5%+ stake

Quest Diagnostics (DGX): T. Rowe Price Associates, Inc. cut its DGX stake below 5% (4.9%) 4.9%

T. Rowe Price Associates, Inc. cut its DGX stake below 5% (4.9%).

4.9%
Stake
5.43M
Shares owned
Stake as of
Jun 30, 2026
Filed
Aug 14, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Mar 10, 2025CongressDisclosed sale of DGX — reported range $15,001 - $50,000
  2. Oct 28, 2025Federal contract · $2.7M obligatedDepartment of Veterans Affairs awarded Quest Diagnostics: $2.75M obligated to date
  3. Oct 30, 2025Congress · 1 personMembers of Congress: 1 purchase, 1 sale
  4. Mar 24, 2026Federal contract · $6.6M obligatedDepartment of Veterans Affairs awarded Quest Diagnostics: $6.57M obligated to date
  5. Mar 27, 2026CongressDisclosed purchase of DGX — reported range $1,001 - $15,000
  6. Mar 30, 2026CongressDisclosed purchase of DGX — reported range $1,001 - $15,000
  7. Apr 1, 2026Federal contract · $3.1M obligatedDepartment of Veterans Affairs awarded Quest Diagnostics: $3.12M obligated to date
  8. May 1, 2026Federal contract · $2.6M obligatedDepartment of Veterans Affairs awarded Quest Diagnostics: $2.6M obligated to date
  9. May 6, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
  10. Jun 1, 2026InsiderCEO sold ~$1.94M of DGX shares in the open market
  11. Jun 4, 2026Insider · Their largest sale since 2024Officer sold ~$1.63M of DGX shares in the open market

What came next

  1. Jul 23, 2026Company filing · Form 8-K · ResultsReported its results
  2. Jul 28, 2026InsiderOfficer sold ~$376K of DGX shares in the open market
  3. Aug 14, 20265% stakeT. Rowe Price Associates, Inc. reported a passive stake (13G) of 4.9%
  4. Aug 28, 2026Insider · 1 personInsiders: 3 sales (~$5.5M)
  5. Sep 1, 2026InsiderCEO sold ~$2.43M of DGX shares in the open market
  6. Sep 29, 2026Federal contract · $3.5M obligatedDepartment of Veterans Affairs awarded Quest Diagnostics: $3.5M obligated to date
  7. Oct 1, 2026Federal contract · $2.7M obligatedDepartment of Veterans Affairs awarded Quest Diagnostics: $2.7M obligated to date
  8. Oct 1, 2026Federal contract · $2.7M obligatedDepartment of Veterans Affairs awarded Quest Diagnostics: $2.7M obligated to date
  9. Oct 1, 2026Federal contract · $3.1M obligatedDepartment of Veterans Affairs awarded Quest Diagnostics: $3.11M obligated to date
  10. Oct 1, 2026Federal contract · $7.2M obligatedDepartment of Veterans Affairs awarded Quest Diagnostics: $7.16M obligated to date
  11. Oct 6, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On October 6, 2026, Quest Diagnostics Incorporated (the “Company”) announced that Catherine T. Doherty will retire in July 2027.”
  12. Oct 22, 2026Company filing · Form 8-K · ResultsReported its results
  13. Oct 26, 2026InsiderDirector sold ~$292K of DGX shares in the open market
View the official recordSEC Schedule 13G

How to read SEC Schedule 13G

A Schedule 13D and a Schedule 13G both disclose beneficial ownership of more than 5% of a US company's voting shares. A 13D is the long form, filed by holders who may seek to influence or control the company, and it must state what they intend to do. A 13G is the short form, open only to passive holders and to certain institutions holding in the ordinary course of business, and it asks no question about intent.

Full guide: Schedule 13D vs Schedule 13G: what is the difference?

What else is on file for Quest Diagnostics

For Quest Diagnostics, OQRO holds 20 insider filings (SEC Form 4 or Form 144), 1 fund holdings report (13F) and 6 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its DGX page.

How this filing works

Explore the data

Common questions

What does this filing report about Quest Diagnostics (DGX) stock?

T. Rowe Price Associates, Inc. cut its DGX stake below 5% (4.9%). Of the company, Schedule 13G (passive).

When did it happen, and when was it made public?

Stake as of: Jun 30, 2026. Filed: Aug 14, 2026.

Is this a trade made on a known date?

No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.

Where does this information come from?

From the SEC Schedule 13G, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Quest Diagnostics recently?

For Quest Diagnostics, OQRO holds 20 insider filings (SEC Form 4 or Form 144), 1 fund holdings report (13F) and 6 federal contract awards dated in the last 90 days. They are listed on the DGX page.

Does this mean DGX stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Quest Diagnostics

Everything OQRO holds on this company is on its DGX page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data